WASHINGTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 1,021,549 shares of its common stock at a purchase price of $1.021 per share. In addition, in a concurrent private placement, the Company is ...

WASHINGTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,021,549 shares of its common stock at a purchase price of $1.021 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, th ...

Investigational Review Board (IRB) approval has been granted for the open-label study to evaluate tafenoquine for treatment of patients with a presumptive diagnosis of chronic babesiosis in outpatient settings.Enrollment expected to commence Q3 2025. WASHINGTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today the approval of an Investigational Review ...

Clinical Study and Market Potential - The first patient has been enrolled in NCT06478641, an expanded access clinical study to confirm the activity of tafenoquine in treating persistent babesiosis in high-risk patients who have failed standard care [1] - Tafenoquine exhibited an 80% cure rate in five high-risk patients with persistent, relapsing babesiosis who had failed prior standard-of-care treatments [2] - The total cumulative accessible market for ARAKODA (tafenoquine) for babesiosis may exceed 400,000 patients through the end of U.S. patent protection in December 2035 [4][8] Tafenoquine and ARAKODA Overview - Tafenoquine is approved for malaria prophylaxis in the U.S. under the product name ARAKODA and in Australia as KODATEF [6] - ARAKODA is indicated for malaria prophylaxis in patients aged 18 years and older, with a long terminal half-life of approximately 16 days, offering potential advantages in less-frequent dosing [6][7] - Tafenoquine was discovered by Walter Reed Army Institute of Research and commercially launched in 2019 [6] Safety and Adverse Reactions - ARAKODA should not be administered to patients with G6PD deficiency, during pregnancy or lactation, or with a history of psychotic disorders [9][10][11][17] - Common adverse reactions include headache, dizziness, back pain, diarrhea, nausea, vomiting, increased alanine aminotransferase, motion sickness, insomnia, depression, abnormal dreams, and anxiety [13] - Serious hypersensitivity reactions, delayed adverse reactions, and psychiatric effects have been observed with ARAKODA use [12] Company Background - 60 Degrees Pharmaceuticals, founded in 2010, specializes in developing and marketing new medicines for infectious diseases [16] - The company achieved FDA approval of ARAKODA for malaria prevention in 2018 and collaborates with research organizations in the U.S., Australia, and Singapore [16] - The company is headquartered in Washington D.C., with a majority-owned subsidiary in Australia [18]

WASHINGTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), pharmaceutical company, and Tufts Medical Center (“Tufts MC”), a leading academic medical center, today announced the signing of a Patent License Agreement to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. Tafenoquine is not currently approved by the U.S. Food and Drug Administration (“FDA”) for the treatme ...

The trial (NCT06207370) evaluates tafenoquine combined with standard treatment for babesiosis, addressing a critical unmet medical need.The clinical site is led by Brigham and Women’s Hospital researchers Ann Woolley, M.D., and David Leaf, M.D.The double-blind, placebo-controlled trial will examine outcomes for hospitalized patients with severe babesiosis, a tick-borne illness often found as a co-infection of Lyme disease. WASHINGTON, Dec. 11, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDA ...

60 Degrees Pharmaceuticals Inc. (SXTP) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $3.60 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -55%. A quarter ago, it was expected that this company would post a loss of $3.96 per share when it actually produced a loss of $4.23, delivering a surprise of -6.82%.Over the last four quarters, the compan ...

Q3 2024 sales revenue increased 164% year-over-year to $135 thousand.Sequential (quarter-over-quarter) net product revenue growth of 8.3%.Gross profit increased from ($20 thousand) to $24 thousand. WASHINGTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today their financial results for the third fiscal quarter of the 2024 year, ended September 30, 2024 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _________ to __________ COMMISSION FILE NUMBER 001-41719 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) | --- | - ...

Highlights include increased ARAKODA® (tafenoquine) brand awareness and utilization through virtual sales outreach using digital behavioral analytics and a co-pay program to assist consumers with out-of-pocket costs. ARAKODA is the only new antimalarial in over a decade and is differentiated by a broad efficacy against all malaria stages, a convenient weekly dosing schedule, and a well-established safety profile. WASHINGTON, Oct. 03, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; S ...